Caxton Associates LP Buys New Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Caxton Associates LP bought a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) in the second quarter, HoldingsChannel.com reports. The fund bought 202,157 shares of the biotechnology company’s stock, valued at approximately $708,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of HRTX. Victory Capital Management Inc. grew its holdings in shares of Heron Therapeutics by 30.2% in the fourth quarter. Victory Capital Management Inc. now owns 19,929 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 4,617 shares in the last quarter. Orchard Capital Management LLC grew its holdings in shares of Heron Therapeutics by 4.7% in the fourth quarter. Orchard Capital Management LLC now owns 2,243,426 shares of the biotechnology company’s stock valued at $3,814,000 after purchasing an additional 100,603 shares in the last quarter. Diversified Trust Co purchased a new position in shares of Heron Therapeutics in the first quarter valued at $66,000. Commonwealth Equity Services LLC grew its holdings in shares of Heron Therapeutics by 3.1% in the first quarter. Commonwealth Equity Services LLC now owns 338,526 shares of the biotechnology company’s stock valued at $938,000 after purchasing an additional 10,122 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Heron Therapeutics in the first quarter valued at $90,000. 80.01% of the stock is owned by hedge funds and other institutional investors.

Heron Therapeutics Stock Up 8.5 %

HRTX stock opened at $2.05 on Friday. Heron Therapeutics, Inc. has a twelve month low of $0.50 and a twelve month high of $3.93. The stock has a market capitalization of $308.84 million, a price-to-earnings ratio of -3.36 and a beta of 1.80. The firm’s fifty day simple moving average is $2.19 and its two-hundred day simple moving average is $2.76.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The firm had revenue of $36.02 million for the quarter, compared to analysts’ expectations of $35.35 million. During the same quarter in the previous year, the firm posted ($0.35) EPS. As a group, equities research analysts expect that Heron Therapeutics, Inc. will post -0.1 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Rodman & Renshaw started coverage on shares of Heron Therapeutics in a report on Thursday, June 13th. They issued a “buy” rating and a $7.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and set a $5.00 price objective on shares of Heron Therapeutics in a research report on Wednesday.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.